鲁邦在印度的工厂通过了美国FDA的检查，发现了一些小问题，但无需紧急修复。 Lupin’s Indian factory passed a U.S. FDA inspection with minor issues noted but no urgent fixes needed.

Lupin's Goa制造设施在2025年11月10日至21日进行检查后,从美国林业发展局收到了一份令人满意的机构检查报告(EIR),并附有自愿行动说明(VAI)分类,其中指出已注意到的小问题,但无需立即采取纠正行动。 Lupin's Goa manufacturing facility received a satisfactory Establishment Inspection Report (EIR) from the U.S. FDA after an inspection from November 10 to 21, 2025, with a Voluntary Action Indicated (VAI) classification, indicating minor issues noted but no immediate corrective action required. 其结果反映了该公司对全球药物生产的质量和合规性的承诺。 The result reflects the company’s commitment to quality and compliance in global drug production. Lupin的股份在BSE上上升0.24%至2 328.70。 Lupin’s shares rose 0.24% to ₹2,328.70 on the BSE.